Abstract
BackgroundAdalimumab, an anti TNF-α agent, has been proven to be safe and effective in treatment of ankylosing spondylitis (AS). A biosimilar adalimumab was approved for use by Indian regulators in...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have